Trial PaperTreatment-Resistant Depression (TRD)Depressive DisordersSubstance Use Disorders (SUD)Neuroimaging & Brain MeasuresKetamine

Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression

This open-label study (n=28) investigated whether ketamine (35mg/70kg) treatment prior to propofol-assisted electroconvulsive therapy (ECT) can improve clinical symptoms of depression. The addition of ketamine improved treatment, and this was accompanied by increased global functional connectivity density in the left temporal and subgenual anterior cingulated cortex and decreased functional connectivity strength within the default mode network for a period of 10 days. However, the remission of depressive symptoms only lasted 7 days.

Authors

  • Zhang, J.
  • Tian, H.
  • Li, J.

Published

Psychiatry Research
individual Study

Abstract

Introduction

New methods for using ketamine in patients with propofol-electroconvulsive therapy-resistant depression (ECTRD) are needed in the clinic.

Methods

This study aimed to investigate the therapeutic efficacy of ketamine plus ECT in ECT-RD patients, along with the treatment-induced brain alterations. A total of 28 ECT-RD patients were intravenously injected with ketamine six times and treated with propofol-ECT six times alternately within two weeks. The Hamilton Depression Scale was used to assess the treatment effect. Global functional connectivity density (gFCD) and functional connectivity strength (FCS) were used to evaluate functional brain alterations.

Results

As compared with the propofol-ECT treatment group, the addition of ketamine could improve the therapeutic outcomes in patients with ECT-RD. The treatment increased gFCD in the left temporal and subgenual anterior cingulated cortex. Simultaneously, the treatment decreased FCS within the default mode network. Although increased functional connectivity could be sustained for 10 days, the clinical effect was only sustained 7 days, indicating that the clinical effect and functional brain alterations were disjointed.

Discussion

Ketamine plus propofol-ECT can obviously improve the effects of propofol-ECT in ECT-RD patients. However, the effect is limited in 7 days, suggesting the benefit is short-term.

Available with Blossom Pro

Research Summary of 'Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression'

Introduction

Depression remains highly prevalent and often refractory to treatment, with many patients classified as treatment-resistant after failing adequate courses of antidepressants from at least two pharmacological classes and psychotherapeutic interventions. Electroconvulsive therapy (ECT) and other neuromodulation approaches provide options for treatment-resistant depression (TRD), but a substantial subset of patients do not respond to ECT administered under propofol anaesthesia; the investigators label these individuals as having ECT-resistant depression (ECT-RD). Prior studies have reported short-lived antidepressant effects of ketamine and ketamine-related alterations in brain structure and function, but the utility of combining ketamine with ECT (or as an anaesthetic during ECT) remains uncertain and may carry safety concerns including cardiovascular and addiction risks. Zhang and colleagues conducted a pilot study to test whether alternating intravenous low-dose ketamine and propofol-anaesthetised bilateral ECT over two weeks improves clinical outcomes and induces measurable changes in brain functional connectivity in patients with propofol-ECT-resistant depression. The study aimed to characterise both the time course of clinical response, assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17), and treatment-associated changes in global functional connectivity density (gFCD) and functional connectivity strength (FCS) within the default mode network (DMN) using repeated resting-state fMRI assessments.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

Related Clinical Trial

References (2)

Papers cited by this study that are also in Blossom

Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice

Bobo, W. V., Vande Voort, J. L., Croarkin, P. E. et al. · Depression and Anxiety (2016)

Ketamine for treatment-resistant depression: recent developments and clinical applications

Schwartz, J., Murrough, J. W., Iosifescu, D. V. · Evidence-Based Mental Health (2016)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Ketamine plus propofol-electroconvulsive therapy... — Research Summary & Context | Blossom